Ademi LLP is investigating possible securities fraud claims against Aldeyra (Nasdaq: ALD). The investigation results from inaccurate statements Aldeyra may have made regarding its financial statements, business operations and prospects.
The investigation focuses on whether Aldeyra disclosed problems in its clinical trials for reproxalap for dry eye disease.
Join this Action